World Journal of Surgery

, Volume 35, Issue 8, pp 1766–1769 | Cite as

The Promise of a Personalized Genomic Approach to Pancreatic Cancer and Why Targeted Therapies Have Missed the Mark

  • William E. FisherEmail author


Pancreatic cancer (PC) carries the highest mortality rate of any cancer type. Although minor advances in chemotherapy have been made, the mortality rate has remained the same over the last several decades. Clinical trials examining therapies targeting the epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), specific mutated proteins such as K-ras, immunotherapy employing tumor-associated antigens, and biologic therapy such as TNFerade (GenVec, Inc., Gaithersburg, MD) have all failed to substantially improve survival. Pancreatic cancer is likely a heterogeneous disease; therefore, a personalized genomic approach offers the possibility to tailor treatment to the unique characteristics of individual patients and their tumors. Rapid advances in sequencing technology are decreasing the time and cost of obtaining this information to a clinically useful level. However, many challenges remain to be faced in applying this technology in the field of PC. Even if patients with PC could be identified early in the course of the disease, localizing the disease and treating it in a minimally invasive fashion will remain problematic. Ethical issues including patient discrimination and access to care will be particularly important in PC. As the field advances, validation, education of clinicians, and determining the true value and source of funding will be difficult. Although the era of personalized genomic medicine has arrived, it will certainly take many years to begin to realize its potential. It is to be hoped that this new approach will result in a significant improvement in the survival curve for patients with PC.


Vascular Endothelial Growth Factor Pancreatic Cancer Bevacizumab Gemcitabine Cetuximab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Altekruse SF, Kosary CL, Krapcho M et al. eds (2010) SEER Cancer Statistics Review, 1975–2007, National Cancer Institute. Bethesda, MD. Available at Accessed December 2010
  2. 2.
    Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  3. 3.
    Neuhaus P, Riess H, Post S et al. (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 26(suppl):abstr LBA4504Google Scholar
  4. 4.
    Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMedCrossRefGoogle Scholar
  5. 5.
    Xiong HQ, Rosenberg A, LoBuglio A et al (2004) Cetuximab a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22:2610–2616PubMedCrossRefGoogle Scholar
  6. 6.
    Philip PA, Benedetti J, Fenoglio-Preiser C et al (2007) Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J Clin Oncol 25(Suppl):18S (SBA4509)Google Scholar
  7. 7.
    Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040PubMedCrossRefGoogle Scholar
  8. 8.
    Kindler HL, Nedzwiecki D, Hollis D et al (2007) A double-blind placebo-controlled randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25(Suppl):18 (SSBA4508)Google Scholar
  9. 9.
    Van Cutsem E, van de Velde HP, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438PubMedCrossRefGoogle Scholar
  10. 10.
    The International Human Genome Mapping Consortium (2001) A physical map of the human genome. Nature 409:934–941CrossRefGoogle Scholar
  11. 11.
    The Celera Genomics Sequencing Team (2001) The sequence of the human genome. Science 1304–1351Google Scholar
  12. 12.
    Wheeler DA, Srinivasan M, Egholm M (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452:872–876PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2011

Authors and Affiliations

  1. 1.The Elkins Pancreas Center, Michael E. DeBakey Department of SurgeryBaylor College of MedicineHoustonUSA

Personalised recommendations